Biotech Holdings Ltd. is an integrated pharmaceutical company based in Vancouver, Canada, engaged in research, development, manufacture and marketing of pharmaceutical products.

The focus of the Company is the manufacturing and international marketing of SucanonTM, a new drug for the treatment of Type II Diabetes. Also known as Glucanin. The Company’s focus remains the development and distribution of Sucanon, particularly in Mexico and Latin America. During the fiscal year ended March 31, 2005, Biotech Holdings Ltd. began the manufacture of Sucanon.

In December 2004, the Company began shipping its Type II Diabetes drug Sucanon to Mexican retailers. On March 3, 2005, the Company announced that there was an expansion in the number of drugstore chains and other retail outlets carrying Sucanon in Mexico. Biotech Holdings Ltd. owns 75% of Smith Rothe Pharmaceutical Inc. (Smith Rothe). Smith Rothe holds the marketing rights for the Company’s Type II Diabetes drug in countries other than Asian Countries.

Following are a few of their investment highlights:

• Sucanon is one of only three drugs approved anywhere in the world, belonging to a new category of drugs called “insulin sensitizers”.
• Sucanon has received regulatory approval in Mexico. Mexico is the eighth largest pharmaceutical market and one of the largest diabetic markets in the world. Complications of diabetes is Mexico’s leading cause of death.
• Sales of the drug began in Mexico in early 2005. Sucanon is now sold in more than 600 stores nationally in Mexico including outlets of at least six drugstore chains.
• Sucanon has been approved in Peru and sales are planned to begin later this year. Preliminary distribution agreements for Sucanon have been negotiated in other Latin American countries.
• Internet sales of Sucanon are also planned.

The current trading price is very low, which is merely $0.05/share. It’s been fluctuating so much starting January 2006 and slowly declining - even though it once went up as high as $0.11/share in August, it quickly dropped again and finally settled at $0.05/share. I personally like the product that they currently develop; however, looking at their stock perfomance in the past 9 months, I have become very hesitant whether I should invest in this stock or not. Hmm..I’ll probably put this one under my stock-watch list and see what is going to happen in the next few months. Yup, we’ll see…….

Source: http://finance.google.com

Quote of the Day:
Each time, it’s a nice little company, nice people, modestly successful. Then you bring in the VC money - it’s like putting jet engines on a VW. They expect that, within a year and a half, they will get back ten times their money. - Dennis Faust